Disease or Syndrome – Page 92

CSL Seqirus Secures Fourth US Award to Enhance Bird Flu Vaccine Stockpile

11 months ago talkbio0Tagged Aves, BARDA, bird flu vaccine, CSHL1 gene, Government, Influenza in Birds, pandemic preparedness, public health protection, Seqirus, U.S., Vaccines

CSL Seqirus, bird flu vaccine, US government award, BARDA, pandemic preparedness, avian influenza, H5N1, vaccine stockpile, public health protection

Novartis Advances Remibrutinib for Chronic Spontaneous Urticaria with Promising Long-term Data

11 months ago talkbio0Tagged Agammaglobulinaemia tyrosine kinase, Chronic Spontaneous Urticaria, Inhibitor, Long-term, Novartis, Oral cavity, Phase 3 Clinical Trials, remibrutinib

Novartis, Remibrutinib, Chronic Spontaneous Urticaria, Phase III Trials, Long-term Data, Oral Treatment, Bruton’s Tyrosine Kinase Inhibitor

Biogen and Ionis’ ALS Treatment Qalsody Receives European Commission Approval

11 months ago talkbio0Tagged Amyotrophic Lateral Sclerosis, authorization, Biogen, Clinical Trials, Commission, European (ethnic group), Ionis, Qalsody, SOD1, SOD1-ALS

Biogen, Ionis, Qalsody, ALS, European Commission, Marketing Authorization, Rare Disease, SOD1-ALS, Neurofilament, Clinical Trials

Ultragenyx Advances Gene Therapy for Glycogen Storage Disease Type Ia Following Phase 3 Success

11 months ago talkbio0Tagged DTX401, gene therapy, GlucoGene, Glycogen storage disease type Ia, Hereditary Diseases, Phase 3 Clinical Trials, Ultragenyx

Ultragenyx, gene therapy, glycogen storage disease type Ia, DTX401, Phase 3 study, GlucoGene, rare genetic diseases

FDA Delays Dupixent Decision for Uncontrolled COPD Treatment, EU Panel Recommends Approval

11 months ago talkbio0Tagged Approved, Chronic Obstructive Airway Disease, dupilumab, Dupixent, EU, Regeneron, sanofi, Uncontrolled, United States Food and Drug Administration

Dupixent, dupilumab, COPD, FDA, EU approval, Sanofi, Regeneron, uncontrolled COPD, treatment delay

FDA Delays Dupixent Decision for COPD by Three Months, EMA Recommends Approval

11 months ago talkbio0Tagged Boreas, Chronic Obstructive Airway Disease, Dupixent, Multiple Acyl Coenzyme A Dehydrogenase Deficiency, Notus, PDUFA, Phase 3 Clinical Trials, Priority Review, Regeneron, sanofi, United States Food and Drug Administration

FDA, Dupixent, COPD, EMA, Regeneron, Sanofi, Priority Review, PDUFA, Boreas, Notus, Phase III Trials

Eli Lilly Invests $5.3 Billion in Indiana Plant to Boost Diabetes and Obesity Drug Production ###

11 months ago talkbio0Tagged alpha 1-antitrypsin, Diabetes, Eli, Eli Lilly, Glucagon-Like Peptide 1, Indiana, Manufacture, Mounjaro, Nordisk, Obesity, Zepbound

Eli Lilly, Diabetes, Obesity, Mounjaro, Zepbound, Tirzepatide, Indiana, Manufacturing, API, Novo Nordisk, GLP-1 drugs

CinRx Secures $73 Million to Foster Biotech Startups and Advance Obesity Treatments

11 months ago talkbio0Tagged CinRx, Obesity, startups

CinRx, biotech startups, obesity drugs, funding, pharmaceuticals

Immunovant Shifts Focus to Next-Generation FcRn Inhibitor IMVT-1402, Delaying Batoclimab Development ###

11 months ago talkbio0Tagged Autoimmune Diseases, Batoclimab, Biological Factors, FCGRT gene, FcRn, Immunovant, IMVT-1402, Inhibitor, Roivant

Immunovant, IMVT-1402, FcRn inhibitor, Batoclimab, Autoimmune diseases, Vyvgart, Roivant, Biopharmaceuticals

Biohaven’s Phase I Data for Lead Protein Degrader Falls Short of Investor Expectations ###

11 months ago talkbio0Tagged Autoimmune Diseases, Expectations, immunoglobulin G, investor, Myasthenia Gravis, Phase I Clinical Trials, protein degrader, Rheumatoid Arthritis

Biohaven, BHV-1300, Protein degrader, IgG reduction, Phase I study, Investor expectations, Autoimmune disorders, Rheumatoid arthritis, Myasthenia gravis